Hepatitis B mother-to-child transmission

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 1, 2004, Pages 133-145

  Ranger Rogez, Sylvie ^a   Denis, François ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

HBsAg; Hepatitis B; Pregnancy; Pregnant women; Prevention; Vaccination

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; CYTIDINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DNA POLYMERASE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LAMIVUDINE; PEDIARIX; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT HEPATITIS B VACCINE; VIRUS DNA; VIRUS PROTEIN;

ACTIVE IMMUNIZATION; ACUTE HEPATITIS; ANTIBODY RESPONSE; ANXIETY DISORDER; BREAST FEEDING; CHILD HEALTH CARE; CHILDBIRTH; CHRONIC HEPATITIS; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TOLERABILITY; ENDEMIC DISEASE; FLU LIKE SYNDROME; HAIR LOSS; HEALTH PROGRAM; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; IMMUNIZATION; INFECTION PREVENTION; INFECTION RISK; INJECTION SITE REACTION; LEUKOPENIA; MOTHER; NEWBORN INFECTION; PASSIVE IMMUNIZATION; PATHOGENESIS; PERINATAL INFECTION; PERINATAL PERIOD; PREGNANCY; REVIEW; RISK REDUCTION; SCREENING TEST; SIDE EFFECT; THROMBOCYTOPENIA; THYROID DISEASE; VACCINATION; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION;

EID: 2942564373     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.2.1.133     Document Type: Review

References (81)

1. MacCallum FO, Bauer DJ. Homologous serum hepatitis. Lancet ii, 691-692 (1947).
2. Blumberg BS, Alter HJ. A 'new' antigen in leukeniic serum. JAMA 191, 541-546 (1967).
3. Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1, 695-698 (1970).
4. Mahoney FJ. Update on diagnosis, management and prevention of hepatitis B virus infection. Clin. Microbiol. Rev. 12, 351-366 (1999).
5. Koff RS. Prevention of Viral Hepatitis. Curr. Treat. Options Gastroenterol. 5, 451-463 (2002).
6. Lau JY, Wright TL. Molecular virology and pathogenesis of hepatitis B. Lancet 342, 1335-1340 (1993).
7. Chang MH, Hsu HY, Ni YH et al. Precore stop codon mutant in chronic hepatitis B virus infection in children: its relation to hepatitis B e seroconversion and maternal hepatitis B surface antigen. J. Hepatol. 28, 915-922 (1998).
8. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin. Infect. Dis. 20, 992-1000 (1995).
9. Boxall E. Screening of pregnant women for hepatitis B. Vaccine 16(Suppl.), S30-33 (1998).
10. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L and Lanier AP. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch. Intern. Med. 150, 1051-1054 (1990).
11. Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT. NIH conference. Hepatocellular carcinoma. Ann. Intern. Med. 108, 390-401 (1988).
12. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect. Dis. 2, 395-403 (2002).
13. Oda T. Viral hepatitis and hepatocellular carcinoma prevention strategy in Japan. Japan J. Cancer Res. 90, 1051-1060 (1999).
14. Andre F. Hepatitis B epidemiology in Asia, the Middle Fast and Africa. Vaccine 18(Suppl. 1), S20-22 (2000).
15. Khuroo MS and Kamili S. Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy. J. Viral Hepat. 10, 61-69 (2003).
16. Tanaka J. Hepatitis B epidemiology in Latin America. Vaccine 18 (Suppl. 1), S17-19 (2000).
17. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Vimolkej L, Yano M. Is there evidence for intrauterine HBV infection in newborns of hepatitis B carrier mothers? Southeast Asian J. Trop. Med. Public Health 28, 365-369 (1997).
18. Xu DZ, Yan YP, Choi BC et al. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J. Med. Virol. 67, 20-26 (2002).
19. Wang Z, Zhang J, Yang H et al. Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies. J. Med. Virol. 71, 360-366 (2003).
20. Towers CV, Asrat T, Rumney P. The presence of hepatitis B surface antigen and deoxyribonudeic acid in amniotic fluid and cord blood. Am. J. Obstet. Gynecol. 184, 1514-1518; discussion 1518-1520 (2001).
21. Alexander JM, Ramus R, Jackson G, Sercely B, Wendel GD Jr. Fisk of hepatitis B transmission after amniocentesis in chronic hepatitis B carriers. Infect. Dis. Obstet. Gynecol. 7, 283-286 (1999).
22. Wang J, Zhu Q, Zhang X. Effect of delivery mode on maternal-infant transmission of hepatitis B virus by immunoprophylaxis. Chin. Med. J. 115, 1510-1512 (2002).
23. Shiraki K. Perinatal transmission of hepatitis B virus and its prevention. J. Gastroenterol. Hepatol. 15(Suppl.), E11-15 (2000).
24. Sterneck M, Kalinina T, Otto S et al. Neonatal fulminant hepatitis B: structural and functional analysis of complete hepatitis B virus genomes from mother and infant. J. Infect. Dis. 177, 1378-1381 (1998).
25. Hill JB, Sheffield JS, Kim MJ, Alexander JM, Sercely B, Wendel GD. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet. Gynecol. 99, 1049-1052 (2002).
26. Wang JS, Zhu QR, Wang XH. Breastfeeding does not pose any additional risk of immunoprophylaxis failure on infants of HBV carrier mothers. Int. J. Clin. Pract. 57, 100-102 (2003).
27. Ordog K, Szendroi A, Szarka K et al. Perinatal and intrafamily transmission of hepatitis B virus in three generations of a low-prevalence population. J. Med. Virol. 70, 194-204 (2003).
28. Chang MH. Hepatitis B: long-term outcome and benefits from mass vaccination in children. Acta Gastroenterol. Belg. 61, 210-213 (1998).
29. Maupas P, Goudeau A, Coursaget P, Drucker J and Bagros P. Immunization against hepatitis B in man. Lancet 1, 1367-1370 (1976).
30. Barin F, Goudeau A, Denis F et al. Immune response in neonates to hepatitis B vaccine. Lancet 1, 251-253 (1982).
31. Belloni C, Avanzini MA, De Silvestri A et al. No evidence of autoimmunity in 6-year-old children immunized at birth with recombinant hepatitis B vaccine. Pediatrics 110, e4 (2002).
32. Lewis E, Shinefield HR, Woodruff BA et al. Safety of neonatal hepatitis B vaccine administration. Pediatr. Infect. Dis. J. 20, 1049-1054 (2001).
33. Jefferson T, Traversa G. Hepatitis B vaccination: risk-benefit profile and the role of systematic reviews in the assessment of causality of adverse events following immunization. J. Med. Virol. 67, 451-453 (2002).
34. Ascherio A, Zhang SM, Hernan MA et al. Hepatitis B vaccination and the risk of multiple sclerosis. N. Engl. J. Med. 344, 327-332 (2001).
35. Biroscak BJ, Fiore AE, Fasano N, Fineis P, Collins MP, Stoltman G. Impact of the thimerosal controversy on hepatitis B vaccine coverage of infants born to women of unknown hepatitis B surface antigen status in Michigan. Pediatrics 111, e645-649 (2003).
36. Hadler SC, Francis DP, Maynard JE et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N. Engl. J. Med. 315, 209-214 (1986).
37. Koff RS. Immunogenicity of hepatitis B vaccines: implications of immune memory. Vaccine 20, 3695-3701 (2002).
38. FitzSimons D, Francois G, Emiroglu N, Van Damme P. Combined hepatitis B vaccines. Vaccine 21, 1310-1316 (2003).
39. Tada H, Yanagida M, Mishina J et al. Combined passive and active immunization for preventing perinatal transmission of hepatitis B virus carrier state. Pediatrics 70, 613-619 (1982).
40. Euler GL, Wooten KG, Baughman AL, Williams WW. Hepatitis B surface antigen prevalence among pregnant women in urban areas: implications for testing, reporting and preventing perinatal transmission. Pediatrics 111, 1192-1197 (2003).
41. del Canho R, Grosheide PM, Mazel JA et al. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 15, 1624-1630 (1997).
42. Milne A, West DJ, Chinh DV, Moyes CD, Poerschke G. Field evaluation of the efficacy and immunogenicity of recombinant hepatitis B vaccine without HBIG in newborn Vietnamese infants. J. Med. Virol. 67, 327-333 (2002).
43. Strine TW, Barker LE, Mokdad AH, Luman ET, Sutter RW, Chu SY. Vaccination coverage of foreign-born children 19 to 35 months of age: findings from the National Immunization Survey, 1999-2000. Pediatrics 110, e15 (2002).
44. Zhu Q, Lu Q, Gu Y, Xu H, Duan S. A preliminary study on interruption of HBV transmission in uterus. Chin. Med. J. 110, 145-147 (1997).
45. Zhu Q, Yu G, Yu H et al. A randomized control trial on interruption of HBV transmission in uterus. Chin. Med. J. 116, 685-687 (2003).
46. Chen DS. Public health measures to control hepatitis B virus infection in the developing countries of the Asia-Pacific region. J. Gastroenterol. Hepatol. 15(Suppl.), E7-E10 (2000).
47. Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med. 336, 1855-1859 (1997).
48. Anonymous. Hepatitis B vaccination-United States, 1982-2002. MMWR Morb. Mortal. Wkly Rep. 51, 549-552, 563 (2002).
49. Mast FE, Mahoney FJ, Alter MJ, Margolis HS. Progress toward elimination of hepatitis B virus transmission in the United States. Vaccine 16(Suppl.), S48-S51 (1998).
50. Papaevangelou G. Hepatitis B immunization programme: lessons learnt in Greece. Vaccine 16(Suppl.), S45-S47 (1998).
51. Zamir C, Dagan R, Zamir D et al. Evaluation of screening for hepatitis B surface antigen during pregnancy in a population with a high prevalence of hepatitis B surface antigen-positive/hepatitis B e antigen-negative carriers. Pediatr. Infect. Dis. J. 18, 262-266 (1999).
52. Da Villa G, Sepe A. Immunization programme against hepatitis B virus infection in Italy: cost-effectiveness. Vaccine 17, 1734-1738 (1999).
53. Da Villa G. Rationale for the infant and adolescent vaccination programmes in Italy. Vaccine 18 Suppl. 1, S31-34 (2000).
54. Stroffolini T, Bianco E, Szklo A et al. Factors affecting the compliance of the antenatal hepatitis B screening programme in Italy. Vaccine 21, 1246-1249 (2003).
55. Bonanni P, Pesavento G, Bechini A et al. Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine 21, 685-691 (2003).
56. Mele A. Progress in prevention and control of hepatitis B: a congress reviewing the first ten years since the introduction of mass vaccination in Italy. J. Med. Virol. 67, 432 (2002).
57. Mele A, Stroffolini T, Zanetti AR. Hepatitis B in Italy: where we are ten years after the introduction of mass vaccination. J. Med. Virol. 67, 440-443 (2002).
58. Huang K, Lin S. Nationwide vaccination: a success story in Taiwan. Vaccine 18 Suppl. 1, S35-38 (2000).
59. Lin HH, Kao JH, Chang TC, Hsu HY, Chen DS. Secular trend of age-specific prevalence of hepatitis B surface and e antigenemia in pregnant women in Taiwan. J. Med. Virol. 69, 466-470 (2003).
60. Kao JH, Hsu HM, Shau WY, Chang MH, Chen DS. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J. Pediatr. 139, 349-352 (2001).
61. Kane MA. Status of hepatitis B immunization programmes in 1998. Vaccine 16 Suppl, S104-108 (1998).
62. Maddrey WC. Hepatitis B: an important public health issue. J. Med. Virol. 61, 362-366 (2000).
63. Van Damme P, Vorsters A. Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001. J. Med. Virol. 67, 433-439 (2002).
64. FitzSimons D, Van Damme P, Emiroglu N et al. Strengthening immunization systems and introduction of hepatitis B vaccine in central and eastern Europe and the newly independent states. Vaccine 20, 1475-1479 (2002).
65. Vranckx R, Alisjahbana A, Meheus A. Hepatitis B virus vaccination and antenatal transmission of HBV markers to neonates. J. Viral Hepat. 6, 135-139 (1999).
66. Euler GL, Copeland JR, Rangel MC, Williams WW. Antibody response to postexposure prophylaxis in infants born to hepatitis B surface antigen-positive women. Pediatr. Infect. Dis. J. 22, 123-129 (2003).
67. Mele A, Tancredi F, Romano L et al. Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy. J. Infect. Dis. 184, 905-908 (2001).
68. Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J. Infect. Dis. 187, 134-138 (2003).
69. Reifenberg K, Deutschle T, Wild J et al. The hepatitis B virus e antigen cannot pass the murine placenta efficiently and does not induce CTL immune tolerance in H-2b mice in utero. Virology 243, 45-53 (1998).
70. Ngui SL, Andrews NJ, Underhill GS, Heptonstall J, Teo CG. Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors. Clin. Infect. Dis. 27, 100-106 (1998).
71. Nainan OV, Khristova ML, Byun K et al. Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J. Med. Virol. 68, 319-327 (2002).
72. Ngui SI, O'Connell S, Eglin RP, Heptonstall J, Teo CG. Low detection rate and maternal provenance of hepatitis B virus S gene mutants in cases of failed postnatal immunoprophylaxis in England and Wales. J. Infect. Dis. 176, 1360-1365 (1997).
73. Oon CJ, Lim GK, Ye Z et al. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 13, 699-702 (1995).
74. Zhou F, Euler GL, McPhee SJ et al. Economic analysis of promotion of hepatitis B vaccinations among Vietnamese-American children and adolescents in Houston and Dallas. Pediatrics 111, 1289-1296 (2003).
75. Alberti A, Brunetto MR, Colombo M, Craxi A. Recent progress and new trends in the treatment of hepatitis B. J. Med. Virol. 67, 458-462 (2002).
76. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 339, 61-68 (1998).
77. Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin. Pharmacokinet. 36, 41-66 (1999).
78. Kazim SN, Wakil SM, Khan LA, Hasnain SE, Sarin SK. Vertical transmission of hepatitis B vinis despite maternal lamivudine therapy. Lancet 359, 1488-1489 (2002).
79. van Zonneveld M, van Nunen AB, Niesters HG et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J. Viral Hepat. 10, 294-297 (2003).
80. Li XM, Yang YB, Hou HY et al. Interruption of HBV intrauterine transmission: A clinical study. World J. Gastroenterol. 9, 1501-1503 (2003).
81. De Clercq E. Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections. Expert Rev. Anti-infect. Ther. 1, 21-43 (2003).